Herantis Pharma Oyj (HEL:HRTIS)

Market Cap	56.38M +71.6%
Revenue (ttm)	n/a
Net Income	-5.45M
EPS	-0.25
Shares Out	24.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,922
Average Volume	65,233
Open	2.320
Previous Close	2.260
Day's Range	2.270 - 2.360
52-Week Range	1.200 - 3.870
Beta	0.30
RSI	52.03
Earnings Date	Mar 5, 2026

About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 13
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: HRTIS